Global Propofol and Ciprofol Injections Market Growth 2026-2032
Description
The global Propofol and Ciprofol Injections market size is predicted to grow from US$ 1458 million in 2025 to US$ 1991 million in 2032; it is expected to grow at a CAGR of 4.6% from 2026 to 2032.
Propofol and ciprofol injections are intravenous short-acting sedative–hypnotic anesthetics used for general anesthesia and procedural sedation. Propofol is supplied as a white oil-in-water injectable emulsion because the drug is poorly water-soluble.
Upstream, the supply chain combines API synthesis and parenteral lipid-emulsion manufacturing with pharmaceutical excipients (e.g., soybean oil, egg lecithin/phospholipids, glycerol. Downstream, these injections are primarily used in hospitals and ambulatory procedure settings (operating rooms/anesthesia departments, endoscopy units, and in some regions ICU sedation), with strict requirements on aseptic handling and single-patient use because lipid emulsions can support microbial growth and are labeled accordingly (including allergy considerations related to egg/soy components in some products).
In 2025, global sales of propofol and ciprofol injections reached approximately 392 million units, with an average global market price of around US$ 3.8/unit. Production capacity varies significantly among manufacturers, with gross profit margins ranging from approximately 50% to 70%.
Propofol and ciprofol injections are short-acting IV sedative–hypnotics used across anesthesia induction/maintenance, procedural sedation (such as endoscopy), and parts of ICU sedation practice. As ambulatory surgery and outpatient procedures expand and anesthesia becomes more titration-driven, healthcare providers increasingly value agents with rapid onset, fast recovery, and controllable depth of sedation—while also paying close attention to hemodynamic fluctuation, respiratory depression, and the patient experience of injection pain, leaving room for product differentiation and formulation optimization.
On the supply side, competition is shaped not only by the API but by the quality system behind lipid-emulsion injectables: choices in the oil phase and emulsifiers (e.g., soybean oil and egg phospholipids) and the microbial-growth control strategy can influence emulsion stability, contamination risk management, and ease of clinical use. Labels for propofol emulsions commonly emphasize strict aseptic handling, single-patient use, and allergy considerations tied to egg/soy components, so reliable supply, batch-to-batch consistency, and documentation/compliance capability often determine access to top-tier hospitals and high-throughput endoscopy chains.
Looking ahead, propofol is highly genericized in many markets, making procurement and cost efficiency central. In parallel, “improved” molecules positioned for potentially smoother hemodynamics and lower injection pain—such as ciprofol in regions where it is approved—are being adopted more rapidly, creating a two-layer structure of high-volume generics plus next-generation alternatives. Building defensible advantage typically requires a combination of clinical evidence, control over critical excipients, robust aseptic fill–finish capabilities, and deep linkage to high-frequency clinical scenarios like anesthesia and GI endoscopy.
LP Information, Inc. (LPI) ' newest research report, the “Propofol and Ciprofol Injections Industry Forecast” looks at past sales and reviews total world Propofol and Ciprofol Injections sales in 2025, providing a comprehensive analysis by region and market sector of projected Propofol and Ciprofol Injections sales for 2026 through 2032. With Propofol and Ciprofol Injections sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Propofol and Ciprofol Injections industry.
This Insight Report provides a comprehensive analysis of the global Propofol and Ciprofol Injections landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Propofol and Ciprofol Injections portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Propofol and Ciprofol Injections market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Propofol and Ciprofol Injections and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Propofol and Ciprofol Injections.
This report presents a comprehensive overview, market shares, and growth opportunities of Propofol and Ciprofol Injections market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Propofol Injections
Ciprofol Injections
Segmentation by Concentration:
1%
2%
Other
Segmentation by Packaging:
10 mL
20 mL
50 mL
100 mL
Segmentation by Application:
General Anesthesia
Medical Procedures Sedation
Mechanical Ventilation
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Fresenius Kabi
Pfizer
B. Braun
Sagent Pharmaceuticals
Dr. Reddy's Laboratories
Rusoma
Centurion Healthcare
Wellona Pharma
Hikma Pharmaceuticals
Avet Pharmaceuticals
Xi’an Libang Pharmaceutical
Guangdong Jiabo Pharmaceutical
Sichuan Biokin Pharmaceutical
Sichuan Kelun Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Jiangsu Yingke Biopharmaceutical
Haisco Pharmaceutical Group
Key Questions Addressed in this Report
What is the 10-year outlook for the global Propofol and Ciprofol Injections market?
What factors are driving Propofol and Ciprofol Injections market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Propofol and Ciprofol Injections market opportunities vary by end market size?
How does Propofol and Ciprofol Injections break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Propofol and ciprofol injections are intravenous short-acting sedative–hypnotic anesthetics used for general anesthesia and procedural sedation. Propofol is supplied as a white oil-in-water injectable emulsion because the drug is poorly water-soluble.
Upstream, the supply chain combines API synthesis and parenteral lipid-emulsion manufacturing with pharmaceutical excipients (e.g., soybean oil, egg lecithin/phospholipids, glycerol. Downstream, these injections are primarily used in hospitals and ambulatory procedure settings (operating rooms/anesthesia departments, endoscopy units, and in some regions ICU sedation), with strict requirements on aseptic handling and single-patient use because lipid emulsions can support microbial growth and are labeled accordingly (including allergy considerations related to egg/soy components in some products).
In 2025, global sales of propofol and ciprofol injections reached approximately 392 million units, with an average global market price of around US$ 3.8/unit. Production capacity varies significantly among manufacturers, with gross profit margins ranging from approximately 50% to 70%.
Propofol and ciprofol injections are short-acting IV sedative–hypnotics used across anesthesia induction/maintenance, procedural sedation (such as endoscopy), and parts of ICU sedation practice. As ambulatory surgery and outpatient procedures expand and anesthesia becomes more titration-driven, healthcare providers increasingly value agents with rapid onset, fast recovery, and controllable depth of sedation—while also paying close attention to hemodynamic fluctuation, respiratory depression, and the patient experience of injection pain, leaving room for product differentiation and formulation optimization.
On the supply side, competition is shaped not only by the API but by the quality system behind lipid-emulsion injectables: choices in the oil phase and emulsifiers (e.g., soybean oil and egg phospholipids) and the microbial-growth control strategy can influence emulsion stability, contamination risk management, and ease of clinical use. Labels for propofol emulsions commonly emphasize strict aseptic handling, single-patient use, and allergy considerations tied to egg/soy components, so reliable supply, batch-to-batch consistency, and documentation/compliance capability often determine access to top-tier hospitals and high-throughput endoscopy chains.
Looking ahead, propofol is highly genericized in many markets, making procurement and cost efficiency central. In parallel, “improved” molecules positioned for potentially smoother hemodynamics and lower injection pain—such as ciprofol in regions where it is approved—are being adopted more rapidly, creating a two-layer structure of high-volume generics plus next-generation alternatives. Building defensible advantage typically requires a combination of clinical evidence, control over critical excipients, robust aseptic fill–finish capabilities, and deep linkage to high-frequency clinical scenarios like anesthesia and GI endoscopy.
LP Information, Inc. (LPI) ' newest research report, the “Propofol and Ciprofol Injections Industry Forecast” looks at past sales and reviews total world Propofol and Ciprofol Injections sales in 2025, providing a comprehensive analysis by region and market sector of projected Propofol and Ciprofol Injections sales for 2026 through 2032. With Propofol and Ciprofol Injections sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Propofol and Ciprofol Injections industry.
This Insight Report provides a comprehensive analysis of the global Propofol and Ciprofol Injections landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Propofol and Ciprofol Injections portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Propofol and Ciprofol Injections market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Propofol and Ciprofol Injections and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Propofol and Ciprofol Injections.
This report presents a comprehensive overview, market shares, and growth opportunities of Propofol and Ciprofol Injections market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Propofol Injections
Ciprofol Injections
Segmentation by Concentration:
1%
2%
Other
Segmentation by Packaging:
10 mL
20 mL
50 mL
100 mL
Segmentation by Application:
General Anesthesia
Medical Procedures Sedation
Mechanical Ventilation
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Fresenius Kabi
Pfizer
B. Braun
Sagent Pharmaceuticals
Dr. Reddy's Laboratories
Rusoma
Centurion Healthcare
Wellona Pharma
Hikma Pharmaceuticals
Avet Pharmaceuticals
Xi’an Libang Pharmaceutical
Guangdong Jiabo Pharmaceutical
Sichuan Biokin Pharmaceutical
Sichuan Kelun Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Jiangsu Yingke Biopharmaceutical
Haisco Pharmaceutical Group
Key Questions Addressed in this Report
What is the 10-year outlook for the global Propofol and Ciprofol Injections market?
What factors are driving Propofol and Ciprofol Injections market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Propofol and Ciprofol Injections market opportunities vary by end market size?
How does Propofol and Ciprofol Injections break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
130 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Propofol and Ciprofol Injections by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Propofol and Ciprofol Injections by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
